Profile data is unavailable for this security.
About the company
Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The Company operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The Company conducts its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)8.17bn
- Net income in HKD2.24bn
- Incorporated2004
- Employees9.70k
- LocationHangzhou Tigermed Consulting Co Ltd15F618 Jiangnan Avenue, Binjiang DistrictHANGZHOU 310051ChinaCHN
- Phone+86 57 189986795
- Fax+86 57 189986795
- Websitehttps://www.tigermedgrp.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keymed Biosciences Inc | 90.39m | -822.61m | 10.06bn | 1.12k | -- | 3.45 | -- | 111.25 | -3.15 | -3.15 | 0.3457 | 10.43 | 0.0207 | 0.3115 | 7.74 | 100,772.90 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| TYK Medicines Inc | 0.00 | -473.75m | 11.05bn | 144.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | -3.12 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -68.75 | -- | -- | -100.00 | -- | -22.97 | -- | -- | -- |
| InnoCare Pharma Ltd | 864.30m | -521.30m | 11.10bn | 1.09k | -- | 1.24 | -- | 12.84 | -0.3086 | -0.3086 | 0.5117 | 4.34 | 0.0786 | 0.9875 | 3.19 | 793,660.90 | -4.88 | -13.41 | -6.20 | -15.36 | 85.59 | 85.99 | -62.04 | -172.16 | 3.77 | -- | 0.1667 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| RemeGen Co Ltd | 1.55bn | -1.76bn | 11.76bn | 3.50k | -- | 2.19 | -- | 7.61 | -3.27 | -3.27 | 2.87 | 5.47 | 0.2411 | 0.4413 | 4.03 | 427,723.50 | -27.42 | -18.66 | -35.04 | -23.75 | 77.11 | 81.94 | -113.72 | -102.88 | 1.06 | -31.34 | 0.4737 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
| Ascentage Pharma Group International | 999.69m | -398.85m | 12.26bn | 574.00 | -- | 14.45 | -- | 12.27 | -1.38 | -1.38 | 3.44 | 2.70 | 0.2998 | 3.49 | 2.19 | 1,714,736.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -6.44 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
| Genscript Biotech Corp | 7.86bn | -1.38bn | 22.99bn | 7.28k | -- | 2.43 | -- | 2.92 | -0.651 | -0.651 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,932.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 2.08bn | -257.70m | 39.78bn | 1.54k | -- | 11.20 | -- | 19.14 | -1.14 | -1.14 | 9.39 | 15.94 | 0.5869 | 9.46 | 167.74 | 1,468,539.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Hangzhou Tigermed Consulting Co Ltd | 8.17bn | 2.24bn | 47.37bn | 9.70k | 11.01 | 1.07 | 17.18 | 5.79 | 2.59 | 2.59 | 9.45 | 26.74 | 0.2585 | 200.14 | 2.22 | 842,639.30 | 7.53 | 11.36 | 10.05 | 14.79 | 38.20 | 41.47 | 29.14 | 42.19 | 2.73 | -- | 0.1204 | 17.47 | 4.21 | 26.28 | 0.5169 | 28.57 | 36.31 | -- |
| Akeso Inc | 2.07bn | -814.05m | 54.94bn | 2.82k | -- | 9.50 | -- | 26.48 | -0.969 | -0.969 | 2.47 | 6.68 | 0.1925 | 0.3565 | 5.27 | 746,850.30 | -8.18 | -11.59 | -9.19 | -13.87 | 92.50 | -- | -42.50 | -42.49 | 4.43 | -2.16 | 0.3922 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
| WuXi Biologics (Cayman) Inc | 18.95bn | 2.91bn | 55.67bn | 12.44k | 19.88 | 1.24 | 11.14 | 2.94 | 0.6741 | 0.6741 | 4.40 | 10.84 | 0.3163 | 5.35 | 2.98 | 1,487,332.00 | 5.57 | 8.28 | 6.85 | 10.25 | 38.66 | 43.25 | 17.60 | 27.46 | 2.62 | -- | 0.0928 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sands Capital Management LLCas of 24 May 2024 | 13.32m | 10.82% |
| Baillie Gifford & Co.as of 20 Jan 2023 | 10.22m | 8.30% |
| Ninety One UK Ltd.as of 31 Dec 2023 | 7.56m | 6.14% |
| UBS Asset Management Switzerland AGas of 05 Sep 2023 | 6.28m | 5.10% |
| Canada Pension Plan Investment Boardas of 05 Jul 2024 | 5.80m | 4.71% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 5.52m | 4.49% |
| E Fund Management Co., Ltd.as of 11 Sep 2024 | 5.05m | 4.10% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 4.26m | 3.46% |
| BlackRock Fund Advisorsas of 01 Sep 2023 | 2.19m | 1.78% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 2.12m | 1.73% |
